Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04568096 |
|
Recruitment Status : Unknown
Verified October 2020 by Mahmoud Ramadan mohamed Elkazzaz, Kafrelsheikh University.
Recruitment status was: Not yet recruiting
First Posted : September 29, 2020
Last Update Posted : October 26, 2020
|
Sponsor:
Kafrelsheikh University
Information provided by (Responsible Party):
Mahmoud Ramadan mohamed Elkazzaz, Kafrelsheikh University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | December 2020 |